OpenLB
Open Library of Bioscience
Advanced Search
Reviews in medical virology
09, 2023;33 (5): e2461.

Reemergence of Marburgvirus disease: Update on current control and prevention measures and review of the literature.

Randa Elsheikh, Abdelrahman M Makram, Hager Selim, Dung Nguyen, Thi Thu Thao Le, Van-Phu Tran, Sarah Abd Elaziz Khader, Nguyen Tien Huy
Author Information
  1. Randa Elsheikh: Deanery of Biomedical Sciences, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK. ORCID
  2. Abdelrahman M Makram: Online Research Club, Nagasaki, Japan. ORCID
  3. Hager Selim: Online Research Club, Nagasaki, Japan. ORCID
  4. Dung Nguyen: Online Research Club, Nagasaki, Japan. ORCID
  5. Thi Thu Thao Le: Online Research Club, Nagasaki, Japan. ORCID
  6. Van-Phu Tran: Online Research Club, Nagasaki, Japan. ORCID
  7. Sarah Abd Elaziz Khader: Online Research Club, Nagasaki, Japan. ORCID
  8. Nguyen Tien Huy: Online Research Club, Nagasaki, Japan. ORCID
PMID: 37208958 DOI: 10.1002/rmv.2461

Abstract

In 1967, the very first case of the Marburgvirus disease (MVD) was detected in Germany and Serbia sequentially. Since then, MVD has been considered one of the most serious and deadly infectious diseases in the world with a case-fatality rate between 23% and 90% and a substantial number of recorded deaths. Marburgvirus belongs to the family of Filoviridae (filoviruses), which causes severe viral hemorrhagic fever (VHF). Some major risk factors for human infections are close contact with African fruit bats, MVD-infected non-human primates, and MVD-infected individuals. Currently, there is no vaccine or specific treatment for MVD, which emphasizes the seriousness of this disease. In July 2022, the World Health Organization reported outbreaks of MVD in Ghana after two suspected VHF cases were detected. This was followed in February and March 2023 with the emergence of the virus in two countries new to the virus: Equatorial Guinea and Tanzania, respectively. In this review, we aim to highlight the characteristics, etiology, epidemiology, and clinical symptoms of MVD, along with the current prevention measures and the possible treatments to control this virus.

Keywords

Marburg virus disease Marburgvirus emerging infectious diseases viral hemorrhagic fever

References

  1. Shifflett K, Marzi A. Marburg virus pathogenesis - differences and similarities in humans and animal models. Virol J. 2019;16(1):165. https://doi.org/10.1186/s12985-019-1272-z
  2. Brauburger K, Hume AJ, Muhlberger E, Olejnik J. Forty-five years of Marburg virus research. Viruses. 2012;4(10):1878-1927. https://doi.org/10.3390/v4101878
  3. Bausch DG, Nichol ST, Muyembe-Tamfum JJ, et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med. 2006;355(9):909-919. https://doi.org/10.1056/NEJMoa051465
  4. Centers for Disease Control and Prevention. History of Marburg Virus Disease (MVD) Outbreaks; 2022. Accessed 19 09 2022. https://www.cdc.gov/vhf/marburg/outbreaks/chronology.html
  5. Towner JS, Khristova ML, Sealy TK, et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol. 2006;80(13):6497-6516. https://doi.org/10.1128/JVI.00069-06
  6. World Health Organization: Marburg virus disease - Ghana. 2022. Accessed 02 04 2023. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON409
  7. World Health Organization: Marburg virus - Ghana. 2022. Accessed 19 09 2022. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON402
  8. World Health Organization: Marburg virus disease - Equatorial Guinea. 2023. Accessed 02 04 2023. https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON444
  9. World Health Organization - Equatorial Guinea: Equatorial Guinea confirms first-ever Marburg virus disease outbreak. 2023. Accessed 02 04 2023. https://www.afro.who.int/countries/equatorial-guinea/news/equatorial-guinea-confirms-first-ever-marburg-virus-disease-outbreak
  10. World Health Organization: Marburg virus disease - United Republic of Tanzania. 2023. Accessed 02 04 2023. https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON451
  11. Geisbert TW. 166 - marburg and ebola hemorrhagic fevers (filoviruses). In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2015:1995-1999.
  12. Wei H, Audet J, Wong G, et al. Deep-sequencing of Marburg virus genome during sequential mouse passaging and cell-culture adaptation reveals extensive changes over time. Sci Rep. 2017;7(1):3390. https://doi.org/10.1038/s41598-017-03318-3
  13. Abir MH, Rahman T, Das A, et al. Pathogenicity and virulence of Marburg virus. Virulence. 2022;13(1):609-633. https://doi.org/10.1080/21505594.2022.2054760
  14. Feldmann H, Muhlberger E, Randolf A, et al. Marburg virus, a filovirus: messenger RNAs, gene order, and regulatory elements of the replication cycle. Virus Res. 1992;24(1):1-19. https://doi.org/10.1016/0168-1702(92)90027-7
  15. Muhlberger E, Sanchez A, Randolf A, et al. The nucleotide sequence of the L gene of Marburg virus, a filovirus: homologies with paramyxoviruses and rhabdoviruses. Virology. 1992;187(2):534-547. https://doi.org/10.1016/0042-6822(92)90456-y
  16. Muhlberger E. Filovirus replication and transcription. Future Virol. 2007;2(2):205-215. https://doi.org/10.2217/17460794.2.2.205
  17. Tapparel C, Maurice D, Roux L. The activity of Sendai virus genomic and antigenomic promoters requires a second element past the leader template regions: a motif (GNNNNN)3 is essential for replication. J Virol. 1998;72(4):3117-3128. https://doi.org/10.1128/JVI.72.4.3117-3128.1998
  18. Enterlein S, Schmidt KM, Schumann M, et al. The marburg virus 3' noncoding region structurally and functionally differs from that of ebola virus. J Virol. 2009;83(9):4508-4519. https://doi.org/10.1128/JVI.02429-08
  19. Leroy EM, Gonzalez JP, Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect. 2011;17(7):964-976. https://doi.org/10.1111/j.1469-0691.2011.03535.x
  20. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest. 2000;80(2):171-186. https://doi.org/10.1038/labinvest.3780021
  21. Bray M, Paragas J. Experimental therapy of filovirus infections. Antivir Res. 2002;54(1):1-17. https://doi.org/10.1016/s0166-3542(02)00005-0
  22. Messaoudi I, Amarasinghe GK, Basler CF. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol. 2015;13(11):663-676. https://doi.org/10.1038/nrmicro3524
  23. Basler CF. Innate immune evasion by filoviruses. Virology. 2015;479-480:122-130. https://doi.org/10.1016/j.virol.2015.03.030
  24. Ramanan P, Shabman RS, Brown CS, Amarasinghe GK, Basler CF, Leung DW. Filoviral immune evasion mechanisms. Viruses. 2011;3(9):1634-1649. https://doi.org/10.3390/v3091634
  25. Kortepeter MG, Dierberg K, Shenoy ES, Cieslak TJ. Medical countermeasures working group of the national ebola T, education center's special pathogens research N. Marburg virus disease: a summary for clinicians. Int J Infect Dis. 2020;99:233-242. https://doi.org/10.1016/j.ijid.2020.07.042
  26. World Health Organization: Marburg virus disease. 2021. Accessed 19 09 2022. https://www.who.int/news-room/fact-sheets/detail/marburg-virus-disease
  27. Ajelli M, Merler S. Transmission potential and design of adequate control measures for Marburg hemorrhagic fever. PLoS One. 2012;7(12):e50948. https://doi.org/10.1371/journal.pone.0050948
  28. Towner JS, Pourrut X, Albarino CG, et al. Marburg virus infection detected in a common African bat. PLoS One. 2007;2(8):e764. https://doi.org/10.1371/journal.pone.0000764
  29. Global Biodiversity Information Facility Secretariat: GBIF Backbone Taxonomy - Rousettus aegyptiacus. 2021. Accessed 19 09 2022. https://www.gbif.org/species/2432953
  30. Amman BR, Jones ME, Sealy TK, et al. Oral shedding of Marburg virus in experimentally infected Egyptian fruit bats (Rousettus aegyptiacus). J Wildl Dis. 2015;51(1):113-124. https://doi.org/10.7589/2014-08-198
  31. Amman BR, Schuh AJ, Albarino CG, Towner JS. Marburg virus persistence on fruit as a plausible route of bat to primate filovirus transmission. Viruses. 2021;13(12):2394. https://doi.org/10.3390/v13122394
  32. Asad A, Aamir A, Qureshi NE, et al. Past and current advances in Marburg virus disease: a review. Infez Med. 2020;28(3):332-345.
  33. Iannetta M, Di Caro A, Nicastri E, et al. Viral hemorrhagic fevers other than ebola and Lassa. Infect Dis Clin. 2019;33(4):977-1002. https://doi.org/10.1016/j.idc.2019.08.003
  34. Bauer MP, Timen A, Vossen A, van Dissel JT. Marburg haemorrhagic fever in returning travellers: an overview aimed at clinicians. Clin Microbiol Infect. 2019;21S:e28-e31. https://doi.org/10.1111/1469-0691.12673
  35. Centers for Disease Control and Prevention: Marburg Hemorrhagic Fever. 2021. Accessed 19 09 2022. https://www.cdc.gov/vhf/marburg/pdf/factsheet.pdf
  36. World Health Organization: Marburg virus - Guinea. 2021. Accessed 19 09 2022. https://www.who.int/emergencies/disease-outbreak-news/item/2021-DON331
  37. Kerber R, Lorenz E, Duraffour S, et al. Laboratory findings, compassionate use of favipiravir, and outcome in patients with ebola virus disease, Guinea, 2015-A retrospective observational study. J Infect Dis. 2019;220(2):195-202. https://doi.org/10.1093/infdis/jiz078
  38. Porter DP, Weidner JM, Gomba L, et al. Remdesivir (GS-5734) is efficacious in cynomolgus macaques infected with marburg virus. J Infect Dis. 2020;222(11):1894-1901. https://doi.org/10.1093/infdis/jiaa290
  39. Woolsey C, Cross RW, Agans KN, et al. A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. PLoS Negl Trop Dis. 2022;16(5):e0010433. https://doi.org/10.1371/journal.pntd.0010433
  40. Saeed U. Contemplating potential chemical therapeutic options to combat marburg virus. Am J Biomed Sci Res. 2021;13(5):561-570. https://doi.org/10.34297/ajbsr.2021.13.001915
  41. Warfield KL, Aman MJ. Advances in virus-like particle vaccines for filoviruses. J Infect Dis. 2011;204(Suppl 3):S1053-S1059. https://doi.org/10.1093/infdis/jir346
  42. Woolsey C, Geisbert JB, Matassov D, et al. Postexposure efficacy of recombinant vesicular stomatitis virus vectors against high and low doses of marburg virus variant Angola in nonhuman primates. J Infect Dis. 2018;218(Suppl l_5):S582-S7. https://doi.org/10.1093/infdis/jiy293
  43. European Centre for Disease Prevention and Control: Factsheet about Marburg virus disease. 2022. Accessed 19 09 2022. https://www.ecdc.europa.eu/en/infectious-disease-topics/z-disease-list/ebola-virus-disease/facts/factsheet-about-marburg-virus
  44. Wellington J, Nur A, Nicholas A, et al. Marburg virus outbreak in Ghana: an impending crisis. Ann Med Surg (Lond). 2022;81:104377. https://doi.org/10.1016/j.amsu.2022.104377
  45. Timen A, Isken LD, Willemse P, et al. Retrospective evaluation of control measures for contacts of patient with Marburg hemorrhagic fever. Emerg Infect Dis. 2012;18(7):1107-1114. https://doi.org/10.3201/eid1807.101638
  46. Gear JS, Cassel GA, Gear AJ, et al. Outbreak of marburg virus disease in johannesburg. Br Med J. 1975;4(5995):489-493. https://doi.org/10.1136/bmj.4.5995.489
  47. Mehedi M, Groseth A, Feldmann H, Ebihara H. Clinical aspects of Marburg hemorrhagic fever. Future Virol. 2011;6(9):1091-1106. https://doi.org/10.2217/fvl.11.79
  48. Clark DV, Jahrling PB, Lawler JV. Clinical management of filovirus-infected patients. Viruses. 2012;4(9):1668-1686. https://doi.org/10.3390/v4091668
  49. Jeffs B. A clinical guide to viral haemorrhagic fevers: ebola, Marburg and Lassa. Trop Doct. 2006;36(1):1-4. https://doi.org/10.1258/004947506775598914
  50. Kerstiens B, Matthys F. Interventions to control virus transmission during an outbreak of Ebola hemorrhagic fever: experience from Kikwit, Democratic Republic of the Congo. J Infect Dis. 1999;179(Suppl 1):S263-S267. https://doi.org/10.1086/514320
  51. Panta G, Richardson AK, Shaw IC. Effectiveness of autoclaving in sterilizing reusable medical devices in healthcare facilities. J Infect Dev Ctries. 2019;13(10):858-864. https://doi.org/10.3855/jidc.11433
  52. Stephens PR, Sundaram M, Ferreira S, et al. Drivers of African filovirus (ebola and marburg) outbreaks. Vector Borne Zoonotic Dis. 2022;22(9):478-490. https://doi.org/10.1089/vbz.2022.0020
  53. Stephens PR, Gottdenker N, Schatz AM, Schmidt JP, Drake JM. Characteristics of the 100 largest modern zoonotic disease outbreaks. Philos Trans R Soc Lond B Biol Sci. 2021;376(1837):20200535. https://doi.org/10.1098/rstb.2020.0535
  54. Adjemian J, Farnon EC, Tschioko F, et al. Outbreak of marburg hemorrhagic fever among miners in Kamwenge and Ibanda Districts, Uganda, 2007. J Infect Dis. 2011;204(Suppl 3):S796-S799. https://doi.org/10.1093/infdis/jir312
  55. Amman BR, Carroll SA, Reed ZD, et al. Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog. 2012;8(10):e1002877. https://doi.org/10.1371/journal.ppat.1002877
  56. European Environmental Agency: Climate change, impacts and vulnerability in Europe 2016: An indicator-based report. 2016. Accessed 19 09 2022. https://www.eea.europa.eu//publications/climate-change-impacts-and-vulnerability-2016
  57. Epstein PR. Is global warming harmful to health? Sci Am. 2000;283(2):50-57. https://doi.org/10.1038/scientificamerican0800-50
  58. Peterson AT, Lash RR, Carroll DS, Johnson KM. Geographic potential for outbreaks of Marburg hemorrhagic fever. Am J Trop Med Hyg. 2006;75(1):9-15. https://doi.org/10.4269/ajtmh.2006.75.1.0750009
  59. Wu X, Lu Y, Zhou S, Chen L, Xu B. Impact of climate change on human infectious diseases: empirical evidence and human adaptation. Environ Int. 2016;86:14-23. https://doi.org/10.1016/j.envint.2015.09.007
  60. Theobald E, Hosken DJ, Foster P, Moyes K. Mines and bats: the impact of open-pit mining on bat activity. Acta Chiropterol. 2020;22(1):157-166. https://doi.org/10.3161/15081109acc2020.22.1.014
  61. World Health Organization. Interim Infection Prevention and Control Guidance for Care of Patients with Suspected or Confirmed Filovirus Haemorrhagic Fever in Health-Care Settings, with Focus on Ebola. World Health Organization; 2014.
  62. Raabea VN, Borcherta M. Infection control during filoviral hemorrhagic Fever outbreaks. J Glob Infect Dis. 2012;4(1):69-74. https://doi.org/10.4103/0974-777X.93765

MeSH Term

Animals
Humans
Marburgvirus
Marburg Virus Disease
Hemorrhagic Fever, Ebola
Disease Outbreaks
Risk Factors
Chiroptera
Ebolavirus
Journal Article Review
Article has an altmetric score of 3

Word Cloud

Created with Highcharts 10.0.0MVDMarburgvirusdiseasevirusdetectedinfectiousdiseasesviralhemorrhagicfeverVHFMVD-infectedtworeviewcurrentpreventionmeasurescontrol1967firstcaseGermanySerbiasequentiallySinceconsideredoneseriousdeadlyworldcase-fatalityrate23%90%substantialnumberrecordeddeathsbelongsfamilyFiloviridaefilovirusescausesseveremajorriskfactorshumaninfectionsclosecontactAfricanfruitbatsnon-humanprimatesindividualsCurrentlyvaccinespecifictreatmentemphasizesseriousnessJuly2022WorldHealthOrganizationreportedoutbreaksGhanasuspectedcasesfollowedFebruaryMarch2023emergencecountriesnewvirus:EquatorialGuineaTanzaniarespectivelyaimhighlightcharacteristicsetiologyepidemiologyclinicalsymptomsalongpossibletreatmentsReemergencedisease:UpdateliteratureMarburgemerging

Similar Articles

Cited By